Guided Therapeutics (GTHP) Current Deferred Revenue (2010 - 2026)
Guided Therapeutics (GTHP) posted Current Deferred Revenue of $189000.0 for Q4 2025, down 72.58% sequentially from $689318.0 in Q3 2025, and down 77.74% YoY from $849000.0 in Q4 2024.
Guided Therapeutics (GTHP) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Guided Therapeutics has reported Current Deferred Revenue for 16 years, with the latest figure at $189000.0 in Q4 2025.
- Quarterly Current Deferred Revenue fell 77.74% year-over-year to $189000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $189000.0 (down 77.74% YoY) and the FY2025 annual result came in at $189000.0, down 77.74% from the prior year.
- Current Deferred Revenue slipped to $189000.0 in Q4 2025 per GTHP's latest filing, from $689318.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $514.0 million in Q1 2022 and troughed at $62000.0 in Q1 2021.
- A 5-year average of $29.3 million and a median of $511050.5 in 2022 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue surged 828932.26% in 2022, then tumbled 99.91% in 2023.
- Over 5 years, Current Deferred Revenue stood at $337315.0 in 2021, then soared by 50.93% to $509101.0 in 2022, then declined by 16.67% to $424225.0 in 2023, then jumped by 100.13% to $849000.0 in 2024, then sank by 77.74% to $189000.0 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $189000.0, $689318.0, and $679000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 189,000.00 |
| Dec 31, 2025 | 189,000.00 |
| Sep 30, 2025 | 689,318.00 |
| Jun 30, 2025 | 679,000.00 |
| Mar 31, 2025 | 670,000.00 |
| Dec 31, 2024 | 849,000.00 |
| Sep 30, 2024 | 748,000.00 |
| Jun 30, 2024 | 747,780.00 |
| Mar 31, 2024 | 748,000.00 |
| Dec 31, 2023 | 424,225.00 |
| Sep 30, 2023 | 450,516.00 |
| Jun 30, 2023 | 445,444.00 |
| Mar 31, 2023 | 487,882.00 |
| Dec 31, 2022 | 509,101.00 |
| Sep 30, 2022 | 509,101.00 |
| Jun 30, 2022 | 513,000.00 |
| Mar 31, 2022 | 514.00 Mn |
| Dec 31, 2021 | 337,315.00 |
| Sep 30, 2021 | 278,000.00 |
| Jun 30, 2021 | 62.00 Mn |